TY - JOUR AU - Deep Inder, Deep Inder AU - Md. Faiz Akram , AU - Seema Manak , AU - Pawan Kumar , PY - 2022/09/10 Y2 - 2024/03/29 TI - Estimating the prevalence of adverse effects following immunization (AEFI) with Covid-19 vaccination and to determine association of AEFI with blood grouping among population of south-west Delhi, India: A descriptive cross-sectional study.: To estimate prevalence of adverse effects following Covid-19 vaccination and their association with ABO-Rh blood grouping if any JF - International Journal of Research in Pharmacology & Pharmacotherapeutics JA - Int. J. of Res. in Pharmacology &Pharmacotherapeutics VL - 11 IS - 3 SE - Articles DO - 10.61096/ijrpp.v11.iss3.2022.135-140 UR - https://ijrpp.com/ijrpp/article/view/440 SP - 135-140 AB - AbstractBackground:  Vaccines against Covid-19 are new and developed through fast track process. The study has been conducted to know prevalence of adverse effects following immunization with Covid-19 vaccination and association between AEFI and blood grouping if any.Methods: The self structured questionnaire based study was conducted over a period of 6 months (February 2021 to July 2021. Vaccine recipients who met inclusion criteria were invited to fill questionnaire using Google forms. Information including demographic characteristics, blood grouping (ABO-Rh type), vaccination, use of analgesics and adverse effects was sought within 3-4 weeks post vaccination. Data generated was analyzed using SPSS version 19 Chicago, USA.Results: Of all the 315 majority participants receiving received CovishieldTM (79.3%) followed by 9.3% CovaxinTM (9.3%)  and others (11.4%). The predominant blood group among participants was B+ (38.3%) followed by O+ (27.5%). About 90% of participants experienced mild to moderate AEFIs following first dose of vaccine. Most common adverse effects were injection site pain 89.6% and 67.8% followed by myalgia 64.2% and 25.3%, fever 26.4% and 7.25%, headache 20% and 13% and sore throat 18.9% and 4%, dry mouth 35.8% and 41% following first and second dose of vaccine respectively. Only 0.5% had serious AEFI, requiring hospitalization. Not a single death was reported during study period.Conclusion: All Covid-19 combating vaccines exhibit favorable safety profile with mild self limiting adverse effects, relieved by analgesic- anti-inflammatory drugs. No association of AEFI with ABO-Rh blood grouping was found in present study.  ER -